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Abstract 
In the present work, paracetamol loaded eudragit based microsponges were prepared using quasi-emulsion 
solvent  diffusion  method.  The  compatibility  of  the  drug  with  various  formulation  components  was 
established. Process parameters were analyzed in order  to optimize the formulation.  Shape and surface 
morphology of the microsponges were examined using scanning electron microscopy. The colon specific 
formulations  were  prepared  by  compression  coating  of  microsponges  with 
pectin:hydroxypropylmethylcellulose  (HPMC)  mixture  followed  by  tabletting. The  in  vitro  dissolution 
studies were done on all formulations and the results were evaluated kinetically and statically. The kinetics 
of release study showed that the release data followed Higuchi matrix and the main mechanism of drug 
release from microsponges was diffusion. In vitro studies exhibited that compression coated colon specific 
tablet formulations started the release the drug at the 6th hour corresponding to the arrival time to proximal 
colon 
Keywords: Microsponge, Colonic delivery, Pectin, Diffusion 
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Introduction
The requirement for an oral colonic drug delivery system is to reduce the drug release to a minimum prior 
to the cecum (1). Colon as a site offers distinct advantages on account of a near neutral pH, a much longer 
transit  time,  reduced  digestive  enzymatic  activity  and  a  much  greater  responsiveness  to  absorption 
enhancers  (2).  These criteria  favour  this distal  part  of the gastrointestinal  tract  (GIT) as a site  for  the 
delivery of vermicides, colonic diagnostic agents and sustained release of drugs in treatment of nectural 
asthma, angina and arthritis (3). A colon-specific drug delivery system should prevent drug release in the 
stomach and small intestine and affect an abrupt onset of drug release upon entry in to the colon (4).
Various approaches have been used for delivery of drugs to the colon via oral route, which include coating 
with pH-dependent polymers, design of time-release dosage forms and the utilisation of carriers that are 
degraded exclusively by the colonic bacteria (5). Every system has advantage as well as disadvantages. The 
poor site-specificity of pH-dependent systems, because of large variations in the pH of the gastrointestinal 
tract,  is  very  well  documented.  The  site-specificity  of  timed-release  dosage  forms  is  considered  poor 
because  of  large  variations  in  gastric  emptying  times and  passage  across  the  ileo-caecal  junction (6). 
However, microflora-activated systems formulated making use of non-starch polysaccharides are highly 
promising because the polysaccharide remain undigested in the stomach and the small intestine and can 
only be degraded by the vast anaerobic microflora of the colon. Further more, this strategy exploiting the 
abrupt increase of the bacteria population and corresponding enzyme activities will also accomplish greater 
site-specificity  of  initial  drug  release  (7).  The  polysaccharides  for  colonic  drug  delivery  are  also 
inexpensive, naturally occurring and abundantly available (8). 
Single  unit  colon  targeted  drug  delivery  systems  may  suffer  from  the  disadvantage  of  unintentional 
disintegration of the formulation due to manufacturing deficiency or unusual gastric physiology that may 
lead to drastically compromised systemic drug bioavailability or  loss of local therapeutic  action in the 
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colon.  Recently  much emphasis  is  being laid  on the  development  of  multiparticulate  dosage forms  in 
comparison to single unit systems because of their potential benefits like increased bioavailability; reduce 
risk of local irritation and predictable gastric emptying (9). 
Microsponges are polymeric delivery systems composed of porous microspheres. They are tiny sponge like 
spherical particles that consist of myriad of interconnecting voids within a non-collapsible structure with 
large  porous  surface  (10).  Moreover,  they  may enhance  stability,  reduce  side  effect  and modify drug 
release favorably (7).
Paracetamol (PCM), an antipyretic and analgesic drug which has been widely used in clinical practice was 
selected as a model drug. It has a short half life in plasma about 1–4 hours.
The present study is aimed at developing microsponge based novel colon specific drug delivery system 
containing PCM. The microsponges of PCM were prepared and characterized. They were formulated as 
colon specific tablets and subjected to in vitro characterization for various attributes.
Matarials and Methods
Materials
Paracetamol was purchased from Jackson Laboratories Pvt. Ltd. Amritsar (India). Eudragit RS-100 was 
kindly  gifted  by  Evonic  India  Pvt.  Ltd.  Mumbai  (India).  Polyvinyl  alcohol  30,000–70,000  (PVA), 
Triethylcitrate, and HPMC (100,000 cps) were purchased from Sigma-Aldrich (USA). Pectinex Ultra SP-L 
(26,000 FDU/mL), Pectin (from citrus fruits, methoxy content 9.4%) and Sodium carboxymethyl cellulose 
(Na-CMC) were procured from Sigma (USA). All chemicals used for analysis were analytical grade.
Methods
Paracetamol loaded microsponge preparation
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Paracetamol microsponges were prepared by quasi-emulsion solvent diffusion method. The internal phase 
consisted of Eudragit  RS-100 (200mg) and triethylcitrate  (1%w/v) dissolved in 5 ml dichloromethane. 
Triethylcitrate (TEC) was used as plasticizer. This was, followed by addition of drug with gradual stirring 
(500 rpm). The internal phase was then poured into polyvinyl alcohol 30,000-70,000 (PVA) solution in 
water,  the  external  phase.  After  8  hour  of  stirring  the  microsponges  were  formed  due  to  removal  of 
dichloromethane from the system. The microsponges were filtered and dried at 40°C for 12 hours. The 
composition of microsponge formulations are given in Table 1.
Fourier transform infrared (FTIR) analysis
FTIR spectra of the drug, physical mixture of drug & eudragit RS-100, formulations FPRS1–FPRS4 were 
recorded  in  potassium  bromide  disc  using  a  Shimadzu  Model  8400  FTIR  spectrometer  to  ascertain 
compatibility.
Differential scanning calorimetric (DSC) analysis
Thermal analysis using DSC was carried out on drug, physical mixture of the drug & eudragit RS-100, and 
formulations FPRS1–FPRS4 (Shimadzu DSC-60 Thermal Analyzer).  Accurately weighed samples were 
loaded  into  aluminum pans  and  sealed.  All  samples  were  run  at  a  heating  rate  of  20oC/min.  over  a 
temperature range 40-430oC.
Morphology 
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The morphology and surface  characteristics  of  the microsponges  were studied using scanning electron 
microscopy (SEM). All the samples were coated with gold–palladium alloy under vacuum. Coated samples 
were then examined using LEO 430 SEM analyzer
Actual drug content and encapsulation efficiency
The weighed amount of drug loaded microsponges (100 mg) was kept in 100 ml phosphate buffer pH 6.8 
for 12 h with continuous stirring. The samples were filtered using 0.45_m membrane filter and the samples 
were analyzed at 256 nm against blank using UV spectrophotometer (UV 1700, Shimadzu, Japan). The 
drug content and encapsulation efficiency were calculated using the following formula (7).
Actual drug content (%) =Mact/Mms × 100 
Encapsulation efficiency (%) =Mact/Mthe × 100 
Where Mact is the actual drug content in microsponges, Mms is the total amount of the microsponges and 
Mthe is the amount of drug added to the microsponges. All analyses were carried out in triplicate.
In-vitro drug release studies of microsponge formulations
The microsponges containing 250 mg of paracetamol ware subjected to in-vitro drug release studies. In-
vitro release studies were carried out in USP basket apparatus with stirring rate 50 rpm at 37±0.5 oC. Initial 
drug release was carried out in 900 ml. of 0.1N HCl for 2 hours followed phosphate buffer pH 6.8 for next 
6 h. Samples were withdrawn at regular intervals of time. The sink conditions were maintained by adding 
equal amount of dissolution medium. The samples were analyzed spectrophotometrically (Shimadzu UV-
1700) at a wavelength of  256 nm. Dissolution tests were performed in triplicate for each sample.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
67
6.
1 
: P
os
te
d 
22
 A
ug
 2
00
9
Preparation of colon specific tablet formulations
The core tablets consisting of microsponges containing 250 mg drug, Na-CMC and magnesium stearate 
were prepared by direct compression method. All tablet constituents were weighed and mixed in motor 
passel for 15 min. Final powder mixture was compressed using 10 mm round flat punches on an eight 
station  tablet  punch  machine  (Cambart,  D-8)  using  1500  kgf/cm2 compression  pressure.  Core  tablet 
formulations are given in Table 2.
Pectin:HPMC (80:20) mixture was used as outer shell for compression coating. The coating material used 
was 400 mg. Fifty percent of coating material was placed in the die cavity and the core tablet was placed in 
centre followed by addition of the remainder of the coating material. The coating material was compressed 
around the core tablet at an applied pressure of 2500 kgf/cm2 using round flat punches (14 mm) on the 
same tabletting machine.
In-vitro drug release studies of colon specific formulations
The  drug  release  studies  were  done  with  the  same  method  used  for  microsponges  and  core  tablets. 
Additionally, Pectinex Ultra SP-L was added to the dissolution medium at 6th hour in order to simulate the 
enzymatic action of the colonic bacteria. Samples were withdrawn periodically and compensated with an 
equal  amount  of  fresh  dissolution  media.  The  samples  were  analyzed  for  drug  content  by  measuring 
absorbance at 256 nm using UV spectrophotometer.
Results and discussion 
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Quasi-emulsion  solvent  diffusion  method  was  used  for  preparation  of  microsponges  because  of  its 
simplicity  and  reproducibility.  Moreover,  it  has  advantage  of  avoiding  solvent  toxicity.  The drug  and 
polymer in the ratios 3:1, 6:1, 9:1, and 12:1 were taken to prepare different microsponge formulations 
namely FPRS1, FPRS2, FPRS3, and FPRS4, respectively. In each formulation, the amounts of polymer 
(200 mg), dichloromethane (5 ml), PVA (0.5% w/v) were kept constant. The microsponge formulations 
were prepared using mechanical stirrer (Remi RQ1217-D) at a stirring rate  of 500 rpm for 8 hours. The 
composition of various microsponge formulations are depicted in Table 1.
The effect of various variables like drug/polymer ratio, stirring rate, volume of internal phase, amount of 
emulsifying agent on the nature of microsponges was studied. 
Effect of drug-polymer ratio on microsponges 
The  morphology  of  the  microsponges  was  studied  by  scanning  electron  microscopy  (SEM).  The 
representative photographs of the microsponges are shown in Figure 1. The microsponges were observed to 
be spherical and uniform with no drug crystals on the surface. The figure 1 shows that drug-polymer ratio 
has considerable effect on the morphology and size of microsponges. It was observed that as the ratio of 
drug to polymer was increased, the particle size decreased. This could probably be due to the fact that in 
high drug to polymer ratios, the amount of polymer available per microsponge was comparatively less. 
Probably in high drug-polymer  ratios  less  polymer  amounts surround the drug and microsponges with 
smaller size were obtained (11). 
Production yield,  actual  drug content,  encapsulation efficiency, and mean particle  size of  formulations 
FPRS1-FPRS4 are  presented  in Table 3.  The production  yield,  actual  drug  content,  and encapsulation 
efficiency of FPRS1-FPRS4 formulations was found to be between 72-75%, 73-91% 98-99%, respectively. 
The  data  obtained  for  various  formulations  in  respect  to  production  yield,  actual  drug  content,  and 
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encapsulation efficiency were subjected to t-test at 95% level of significance. No significant difference in 
relation to these parameters was observed amongst various formulation at p <0.05.
Effect of stirring rate on the morphology and yield of microsponges 
The effect of stirring rate on the morphology of microsponges is shown in Figure 2. The formulation with 
the lower  drug to  polymer  ratio  (i.e.,  3:1)  was chosen to  investigate the  effect  of  stirring  rate  on the 
morphology of microsponges. The stirring rate was varied in the range of 300 to 500 rpm. The dispersion 
of the drug and polymer into the aqueous phase was found to be dependant on the agitation speed. As the 
speed  was  increased  the  size  of  microsponges  was  reduced  and  the  microsponges  were  found  to  be 
spherical  and  uniform  (12). When  the  rate  of  stirring  was  increased  up  to  500  rpm  the  spherical 
microsponges were formed with mean particle size of 62.34±6.89 µm. 
It was noted that at higher stirring rate the production yield was decreased. Possibly at the higher stirring 
rates the polymer adhered to paddle due to the turbulence created within the external phase, and hence 
production yield decreased (13). 
Effect of volume of internal phase on the production of microsponges 
It was observed that on increasing the volume of internal phase from 5 to 10 ml microsponges were not 
formed.  This  may  be  due  to  the  decrease  in  viscosity  of  internal  phase (14).  As  the  amount  of 
dichloromethane was increased, the finely dispersed spherical quasi-emulsion droplets were seen in solvent 
under the agitation, but as the stirring was discontinued emulsion droplets adhered together and coalesce. 
Consequently, no microsponges could be formed. The result suggests that the amount of dichloromethane 
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need  to  be  controlled  within an appropriate  range  to  effect  not  only the  formation  of  quasi-emulsion 
droplets  at  the initial  stage but  also the solidification  of  drug and polymer  in  the droplets.  The good 
microsponges were produced when 3 to 5 ml of dichloromethane was used. 
Effect of amount of emulsifying agent on the production yield and particle size of microsponges 
An increase in amount of emulsifying agent resulted in decreased production yield and increased mean 
particle  size.  As the emulsifier  was non-ionic in nature  and possibly formed some hydrophobic region 
which dissolved some of the drug and polymer. The molecules might have associated away from the oil-
water interface at higher concentrations resulting in alternative hydrophobic region which dissolved some 
portion  of  drug  resulting  in  a  reduction  in  production  yield of  microsponges  (13).  On the  other  hand 
increase in the amount of emulsifying agent resulted in increased larger microsponges. This could be due to 
the increased  viscosity wherein larger  emulsion droplets  formed resulting in larger  microsponges.  The 
dispersion  of the solution of  the drug and polymer  into droplets  was effected by the concentration  of 
polyvinyl alcohol in the external phase. When the concentration of PVA was increased in dispersion phase, 
the size of microsponges was found to be decreased (18). The results of the effect of emulsifying agent on 
production yield and mean particle size are shown in table 4. The production yield and mean particle size 
was  greatly  effected  by  the  amount  of  emulsifying  agent.  As  increased  amount  of  emulsifying  agent 
decreased the production yield from 72 to 67 and increased the mean particle size from 62 to 66 µm.
Characterization of microsponges
DSC studies  were  carried  out  to  confirm  compatibility  (15).  The thermal  behavior  of  drugs,  physical 
mixture of drug and polymer, and formulations FPRS1–FPRS4 was studied. In the thermogram, the drug 
showed a sharp endothermic peak (at 174.23 °C) which corresponds to the melting point of drug in the 
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crystalline form. In the DSC curve of physical mixture of drug and polymer, and formulations FPRS1–
FPRS4,  the  characteristic  peaks  of  drug(s)  were  observed.  The  result  showed  that  there  is  no 
incompatibility between drug and polymers. Microsponge production process did not change the nature of 
drug in microsponges. The thermal behavior of the drug, physical mixture of drug & eudragit RS-100 and 
formulations FPRS1–FPRS4 are presented in figure-3. 
FTIR spectra were recorded to assess the compatibility of the drug and excipients (16). FTIR spectra of 
drug, physical mixture of drug & Eudragit RS-100 and formulations FPRS1–FPRS4 were examined. In 
FTIR spectra of paracetamol powder,  characteristic N-H stretching band at 3325 cm 1, O-H stretching−  
band at 3161.11 cm 1, and carbonyl stretching band at 1654 cm 1 were seen. Eudragit RS 100 showed an− −  
ester C=O stretching peak around 1726.17 cm 1. All characteristic peaks of paracetamol were observed in−  
the  FTIR spectra  of  FPRS1–FPRS4 formulations.  The  results  showed that  no  chemical  interaction  or 
changes took place during preparation of the formulations and the drug was found to be stable in all the 
formulations. The FTIR spectra of the drug, physical mixture of drug & eudragit RS-100 and formulations 
FPRS1–FPRS4 are presented in figure-4. 
In-vitro release studies of the microsponge formulations 
The microsponge formulations  were subjected to in-vitro  release  studies using USP XX1V dissolution 
assembly at the stirring rate at 50 rpm and temperature at 37±0.5 oC. Initially drug release was carried out 
in of 0.1N hydrochloric acid for 2 hours followed by phosphate buffer pH 6.8 for next 6 hours. 
The release profiles obtained for the formulations FPRS1-FPRS4 are presented in Figure 5. It was observed 
that the drug release decreased with increase in the amount of polymer for each formulation. This may be 
due to the fact that the release of drug from the polymer matrix takes place after complete swelling of the 
polymer  and  as  the  amount  of  polymer  in  the  formulation  increases  the  time  required  to  swell  also 
increases. The release showed a bi-phasic pattern with an initial burst effect. In the first hour drug release 
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was found to be 17-30 %. This may be attributed to the drug present in the pores of the microsponges or  
improper entrapment of drug (17). The cumulative percent release for FPRS1-FPRS4 at the end of 8 h was 
found to be 54-83 %. The microsponge formulations were subjected to in-vitro dissolution studies and the 
data was analyzed using various mathematical models. Based on highest regression value the best fit was 
observed for Higuchi matrix. The n value for Peppas model was found to be between 0.5-1 indicative of 
non-fickian diffusion.  
The in-vitro dissolution data was subjected to statistical analysis using ANOVA. The p value was found to 
be 0.5207 indicating no significant difference in the release behaviour (p>0.05).
In-vitro dissolution studies of the colon specific tablet formulations 
In order to prepare the compression coated tablet formulations, core tablets were prepared as the first step. 
The homogenous granular  characteristic of microsponges is due to their highly porous structure and in 
these means,  microsponges have the compressibility  to produce strong tablets and 1000–2000 kgf/cm2 
pressure did not cause the structure deformation of microsponges (19). In vitro drug release studies of the 
colon specific tablet formulations were carried out using USP basket apparatus with stirring rate 50 rpm at 
37±0.5 oC. The release profiles obtained for the formulations CPRS1-CPRS4 are presented in figure-6. No 
drug  was released  in  the first  6  hours.  After  this  lag time of  6  hours,  the  drug  release  started  at  the 
beginning 7th hour due to the addition of the Pectinex Ultra SP-L and continued up to 14th hour for CPRS1 
(68.65%),  14th hour  for  CPRS2 (88.23%),  13th  hour  for  CPRS3 (92.45%) and 12th hour  for  CPRS4 
(95.76%).
The results of in vitro drug release showed that the ratio of Pectin: HPMC (80:20) protected the cores up to 
6th hour corresponding to the time to reach the colon and after that under the influence of the enzyme, the 
system could be degraded faster and deliver the drug to the proximal colon that forms the main site of 
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bacterial carbohydrate metabolism. So, the results were in accordance with the triggering mechanism due 
to the very active metabolism in the proximal part compared with the distal part of colon and pectin could 
find the appropriate environment to be degraded.
Conclusion
This  study  presents  new  approach  for  the  preparation  of  modified  microsponges.  The  prepared 
microsponges  exhibited  characteristics  of  an  ideal  delivery  system  for  colon  targeting.  The  unique 
compressibility of microsponges offers a new alternative for producing mechanically strong tablets. Further 
colon specific tablets based on microsponges could provide effective local action as microsponges may 
selectively be taken up by the macrophages present in colon.
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Figure 1 (a-h) SEM photograph of microsponge formulations (drug: eudragit RS-100.    The photograph 
coded ‘A’ represents whole image; ‘B’ represents surface photographs.
Figure 2 SEM Photograph of drug: eudragit RS-100 microsponges prepared at different    stirring rates of 
(a) 300 rpm; (b) 400 rpm; (c) 500 rpm
Figure 3 DSC Thermogram of Paracetamol, Physical mixture of drug & Eudragit RS-100, and FPRS1-
FPRS4 microsponges formulations
Figure 4 FTIR spectra of Paracetamol, Physical mixture of drug & Eudragit RS-100, and FPRS1-FPRS4 
microsponges formulations
Figure 5 In vitro drug release profile of different formulations of microsponges (FPRS1-FPRS4)
Figure 6 In vitro drug release profile of drug from different colon-specific formulations (CPRS1-CPRS4)
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Table-1 Composition of various microsponge formulations
Components
Formulations
FPRS1 FPRS2 FPRS3 FPRS4
Paracetamol (mg) 600 1200 1800 2400 
Eudragit RS-100 (mg) 200 200 200 200 
Triethylcitrate (ml) 1 1 1 1
Dichloromethane (ml) 5 5 5 5
PVA (0.5% w/v) 0.5 0.5 0.5 0.5
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Table 2 Core tablet formulations of PCM microsponges
Core tablet 
formulation 
codes
Microsponges formulations (mg) 
FPRS1 FPRS2 FPRS3 FPRS4
Na-CMC
(mg)
Magnesium 
stearate (mg)
CPRS1 350.0 - - - 42 8
CPRS2 - 300 - - 92 8
CPRS3 - - 290 - 102 8
CPRS4 - - - 280 112 8
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Table-3 Production yield, actual drug content, encapsulation efficacy, and mean particle size 
of various microsponges formulations (n=3)
Formulation Drug:Polymer 
Ratio
production 
yield 
(% ± S.D.)
theoretical
drug 
content 
(%)
actual drug 
content 
 (% ± S.D.)
encapsulation
efficiency 
 (% ± S.D.)
Mean 
Particle 
size  
(µm ± 
S.D.)
FPRS1
FPRS2
FPRS3
FPRS4
3:1
6:1
9:1
12:1
72±0.43
74.12±0.34
76.23±0.36
75.02±0.60
75.00
85.71
90.00
92.30
73.56±0.09
84.32±0.04
88.32±0.45
90.81±0.34
98.08±0.89
98.37±0.56
98.13±0.09
98.38±0.67
62.34±6.89
54.67±5.39
48.23±7.24
41.45±5.34
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Table 4  The effect of emulsifying agent on microsponges formulation
Formulation
Code
Internal Phase External Phase
PCM 
(mg)
Polymer
(mg)
Dichloro-
methane
(ml)
Water 
(ml)
PVA
(% w/v)
 Yield (%)
Mean 
Diameter
µm ± S.D.
FPRS1 (a) 600 200 5 100 0.5 72±0.43 62.34±6.89
FPRS1 (b) 600 200 5 100 1.0 67.35±2.56 66.12±3.15
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Table 5 In vitro drug release models for different microsponges formulations.
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Code
Zero Order First order Higuchi /model Korsmeyar-Peppa’s 
Model
R K
(mg/hr)
R K
(hr-1)
R K
(mg/hr-1/2)
R ‘n’
FPRS1 0.9729 7.7948 0.9846 0.1255 0.9848 24.347 0.9558 0.7939
FPRS2 0.9710 8.3785 0.9869 0.1497 0.9895 26.535 0.9622 0.6829
FPRS3 0.9805 9.4463 0.9941 0.2057 0.9954 29.678 0.9849 0.6323
FPRS4 0.9865 11.296 0.9934 0.3473 0.9957 35.083 0.995088 0.6908
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